INS and diabetes mellitus: Insulin Icodec, the first approved once-weekly insulin analog, provides evidence of substantial non-inferiority compared to once-daily basal analogs in diabetes management in both insulin-naïve and insulin-treated patients who failed to achieve adequate glucose control.